Orthofix Medical
OFIX
150 hedge funds and large institutions have $597M invested in Orthofix Medical in 2023 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 50 increasing their positions, 59 reducing their positions, and 21 closing their positions.
9% more capital invested
Capital invested by funds: $546M → $597M (+$51.2M)
1.85% more ownership
Funds ownership: 89.33% → 91.18% (+1.9%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
7% less funds holding
Funds holding: 162 → 150 (-12)
15% less repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 59
52% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 21
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $5K
Top Buyers
| 1 |
AC
Armistice Capital
New York
|
+$11.2M |
| 2 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$6.51M |
| 3 |
ECM
ExodusPoint Capital Management
New York
|
+$5.92M |
| 4 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
+$3.77M |
| 5 |
First Eagle Investment Management
New York
|
+$3.26M |
Top Sellers
OFIX Hedge Fund Activity: Q2 2023 in Review
150 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Orthofix Medical (OFIX) for Q2 2023, worth a combined $597M — up 9.4% from $546M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of OFIX and 10 opened new positions — a net loss of 11 holders — while 59 trimmed existing stakes and 50 added.
The largest buyer was Armistice Capital, adding an estimated $11.2M. The largest seller was JP Morgan Chase, cutting an estimated $7M.
- 150 institutional investors held Orthofix Medical (OFIX) as of Q2 2023, down from 162 in Q1 2023.
- Funds reported $597M of Orthofix Medical stock for Q2 2023, up 9.4% quarter-over-quarter.
- 10 funds opened new Orthofix Medical positions in Q2 2023 and 21 closed out, a net change of -11 holders.
- The largest Orthofix Medical buyer in Q2 2023 was Armistice Capital, an estimated $11.2M added.
- The largest Orthofix Medical seller in Q2 2023 was JP Morgan Chase, an estimated $7M sold.
Based on aggregated 13F filings for Q2 2023.